THE newer generation of
anticoagulants aka NOACs (novel
oral anti-coagulants) have been
found to reduce the risk of
bleeding compared with older
anticoagulants like warfarin, when
used to prevent clots in people who
also have mild to moderate chronic
kidney disease (CFD), reports the
UK’s National Institute for Health
Research (NIHR).
The products have been well
tested in healthy people with
atrial fibrillation or at risk of
thromboembolism but this was the
first review to look at their safety,
in terms of bleeding and risk of
bleeding within the brain, in people
with kidney disease, said the NIHR.The above article was sent to subscribers in Pharmacy Daily's issue from 03 May 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 May 16
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.